Radiation-induced Esophagitis in Breast Cancer Patients Treated With Supraclavicular Field Irradiation.

IF 1.6 4区医学 Q4 ONCOLOGY

Anticancer research Pub Date : 2024-10-01 DOI:10.21873/anticanres.17283

Zahra Mohammed Ahmed, Mohamed Abouegylah, Gehan A Khedr, Hans Theodor Eich, Khaled Elsayad, Ashraf Mahmoud Elenbaby

{"title":"Radiation-induced Esophagitis in Breast Cancer Patients Treated With Supraclavicular Field Irradiation.","authors":"Zahra Mohammed Ahmed, Mohamed Abouegylah, Gehan A Khedr, Hans Theodor Eich, Khaled Elsayad, Ashraf Mahmoud Elenbaby","doi":"10.21873/anticanres.17283","DOIUrl":null,"url":null,"abstract":"Background/aim: The objective of this research was to assess the frequency and intensity of radiation-induced esophagitis in breast cancer patients treated with supraclavicular radiotherapy field irradiation.Patients and methods: This study involved 100 patients with positive lymph nodes receiving radiotherapy to the breast or chest wall along with supraclavicular field irradiation, with toxicity levels assessed weekly. Treatment utilized the 3D conformal technique, and variables, such as mean and maximum dose to the cervical esophagus, mean dose to the entire esophagus, and length of the esophagus within the treated area were recorded.Results: The occurrence of grade 2 or higher esophagitis was 48%, with patients facing the risk of developing such esophagitis at an average dose of 13 Gy. The probability of grade 2 esophagitis occurring at doses exceeding 13 Gy was statistically significantly higher (p<0.001) with an odds ratio of 24.4.Conclusion: Limiting the mean cervical esophagus dose to <13 Gy could help reduce the frequency and severity of grade 2 or higher toxicity.","PeriodicalId":8072,"journal":{"name":"Anticancer research","volume":"44 10","pages":"4543-4549"},"PeriodicalIF":1.6000,"publicationDate":"2024-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Anticancer research","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.21873/anticanres.17283","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q4","JCRName":"ONCOLOGY","Score":null,"Total":0}

引用次数: 0

Abstract

Background/aim: The objective of this research was to assess the frequency and intensity of radiation-induced esophagitis in breast cancer patients treated with supraclavicular radiotherapy field irradiation.

Patients and methods: This study involved 100 patients with positive lymph nodes receiving radiotherapy to the breast or chest wall along with supraclavicular field irradiation, with toxicity levels assessed weekly. Treatment utilized the 3D conformal technique, and variables, such as mean and maximum dose to the cervical esophagus, mean dose to the entire esophagus, and length of the esophagus within the treated area were recorded.

Results: The occurrence of grade 2 or higher esophagitis was 48%, with patients facing the risk of developing such esophagitis at an average dose of 13 Gy. The probability of grade 2 esophagitis occurring at doses exceeding 13 Gy was statistically significantly higher (p<0.001) with an odds ratio of 24.4.

Conclusion: Limiting the mean cervical esophagus dose to <13 Gy could help reduce the frequency and severity of grade 2 or higher toxicity.

查看原文本刊更多论文

接受锁骨上野外放射治疗的乳腺癌患者因放射引起的食道炎

背景/目的：本研究的目的是评估接受锁骨上放射治疗野照射的乳腺癌患者放射治疗诱发食管炎的频率和强度：这项研究涉及100名淋巴结阳性患者，他们在接受乳房或胸壁放疗的同时接受锁骨上野照射，每周评估毒性水平。治疗采用三维适形技术，并记录了颈部食管的平均和最大剂量、整个食管的平均剂量以及治疗区域内食管的长度等变量：2 级或以上食管炎的发生率为 48%，平均剂量为 13 Gy 时，患者面临发生此类食管炎的风险。剂量超过 13 Gy 时，发生 2 级食管炎的概率明显更高（p）：将颈部食管的平均剂量限制在

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Anticancer research 医学-肿瘤学

CiteScore

3.70

自引率

10.00%

发文量

566

审稿时长

2 months

期刊介绍： ANTICANCER RESEARCH is an independent international peer-reviewed journal devoted to the rapid publication of high quality original articles and reviews on all aspects of experimental and clinical oncology. Prompt evaluation of all submitted articles in confidence and rapid publication within 1-2 months of acceptance are guaranteed. ANTICANCER RESEARCH was established in 1981 and is published monthly (bimonthly until the end of 2008). Each annual volume contains twelve issues and index. Each issue may be divided into three parts (A: Reviews, B: Experimental studies, and C: Clinical and Epidemiological studies). Special issues, presenting the proceedings of meetings or groups of papers on topics of significant progress, will also be included in each volume. There is no limitation to the number of pages per issue.